Research material and lot documents
KLOW vs GLOW vs Wolverine peptide comparisons start with shared ingredients: all three cited examples contain BPC-157 and TB-500, GLOW adds GHK-Cu, and KLOW also includes KPV.
KLOW peptide components and amounts gives the reference identities. The supplier examples below specify their own contents and packaging; the blend names alone do not make those recipes universal.
Components: GHK-Cu, BPC-157, TB-500 and KPV.
Stated amounts: 50 mg, 10 mg, 10 mg and 10 mg, respectively.
Total: 80 mg, as stated on the listing.
Packaging in the cited example: one blend vial.
Supplier source: KLOW kit and linked vial listing at Curo.
Components: GHK-Cu, BPC-157 and TB-500.
Stated amounts: 50 mg, 10 mg and 10 mg, respectively.
Total: 70 mg from adding the listed amounts.
Packaging in the common market form: one blend vial.
GLOW is a market name, not a registered identity.
Components: BPC-157 and TB-500.
Stated amounts: 5 mg of each component.
Total: two 5 mg vials, 10 mg combined by arithmetic.
Packaging in the cited example: separate vials, without premixing.
Supplier source: Curo's recovery catalog and linked pair listing.
The 2008 KPV study used human-derived intestinal epithelial and Jurkat cell models and chemically induced colitis in mice. The authors investigated PepT1-mediated uptake and reported reduced inflammatory measures. Source: 2008 KPV cell and mouse study, PMID 18061177. This study tested neither GLOW nor KLOW, so it cannot decide which blend has a better result.
A 2026 rat Achilles tendon experiment tested BPC-157, a material called synthetic thymosin beta-4 (TB-500), and a combination group. The authors reported no added benefit for the combination over either material alone. Source: 2026 BPC-157 and TB-500 rat study, PMID 42542926.
GHK-Cu and KPV were absent. The abstract also does not establish whether the paper's TB-500 material matches the acetylated fragment in FDA TB-500 fragment identity record. This experiment cannot supply a KLOW result or resolve every possible interaction.
Check the per-component amounts and whether the listing describes a blend vial or a separately packaged stack. Then match the material names to their identity records, particularly for TB-500. The KLOW research-material checks cover the analytical documents.
No direct study of the specified four-component KLOW formulation was located in the October 14, 2026 research. The exact four-name searches returned zero records in PubMed and ClinicalTrials.gov; differently named or unindexed work could be missed. Sources: Dated four-component PubMed search and Dated four-component ClinicalTrials.gov search.
The KLOW peptide research page separates those search findings from the component and pair experiments.